GSK snags first-in-class FDA nod for Rukobia to treat HIV patients who have few options
Rukobia,
a first-in-class attachment inhibitor by GlaxoSmithKline's ViiV Healthcare,
has won FDA approval to treat multidrug-resistant HIV. (Business ...
|
View article...